Stage II Breast Cancer Completed Phase 2 Trials for Pegfilgrastim (DB00019)

IndicationStatusPhase
DBCOND0029484 (Stage II Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00119262Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerTreatment
NCT00146562Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast CancerTreatment